Anti-bacterial antibodies in Epstein-Barr virus (EBV)-transformed oligoclonal B-cell lines established from normal persons and autoimmune disease patients.
We have established 950 and 430 oligoclonal B-lymphoblastoid cell lines (LCL) from two normal persons and eight autoimmune disease patients, respectively by using Epstein-Barr virus (EBV)-induced transformation. To re-evaluate the EBV technique for production of human monoclonal antibodies (mAb) related to infectious disease, we screened these oligoclonal LCLs for antibodies against 31 bacterial strains systematically. A total of 74 cultures out of 1380 were reactive to a total of 18 strains out of 31. Among these, eight cultures showed 10(-3) antibody (Ab) titers to Pseudomonas aeruginosa serotypes C, E, F and I, Staphylococcus aureus, Serratia marcescens and Bacillus cereus. Ten cultures showed 10(-2) Ab titers to Ps. aeruginosa serotypes D, E, F and I, Ps. maltophilia, Staph. epidermidis, Klebsiella ozaenae, Ser. marcescens and B. subtilis. The results reveal the further possibilities for the EBV technique to produce various infectious disease-related human mAbs.
Nagatsuka
Y
Y
Department of Microbiology, Nihon University, School of Medicine, Tokyo, Japan.
Hanazawa
S
S
Koroiwa
Y
Y
Fukuda
T
T
Suganuma
T
T
Ono
Y
Y
D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000302:isolation & purification*; D001327:Autoimmune Diseases / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology*; D002461:Cell Line, Transformed; D005260:Female; D004854:Herpesvirus 4, Human; D006801:Humans; D007218:Industrial Microbiology / Q000379:methods*; D008213:Lymphocyte Activation; D008297:Male
D000907:Antibodies, Bacterial